A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Control Participants
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Batoprotafib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 28 Feb 2024 Planned End Date changed from 12 Jun 2024 to 15 Jul 2025.
- 28 Feb 2024 Planned primary completion date changed from 12 Jun 2024 to 15 Jul 2025.
- 28 Feb 2024 Planned initiation date changed from 15 Feb 2024 to 19 Mar 2025.